Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Gilead GILD

Gilead live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Frances Wang 2024 Dec 17, 16:00

Nikkei 225 performance today: Beginner’s guide to Japan’s stock market

Indices Stocks
Frances Wang 2024 Dec 16, 16:00

MicroStrategy Stock Price: MSTR stock saw an increase of 0.15% today

Stocks
Frances Wang 2024 Dec 16, 16:00

Gold price today: gold holds two-day decline ahead of Fed rate cut

Commodities Gold
Frances Wang 2024 Dec 16, 16:00

Latest cryptocurrency news: What is bitcoin, Ethereum explained

Cryptocurrencies
Frances Wang 2024 Dec 15, 16:00

Broadcom stock price soars 23% as AI revenues spike 220%

Stocks
Dyogenes Diniz 2024 Dec 15, 16:00

Morning Note: Tesla Hits Record High Amid US PMI Focus and Bitcoin's Next Move

Cryptocurrencies US500 EUR USD
US interest rate and Europe inflation to guide market direction
Dyogenes Diniz 2024 Dec 13, 22:00

Week ahead: US Interest rate and Inflation in Europe to determine Markets Direction - Crucial Week

Forex Indices
Frances Wang 2024 Dec 12, 16:00

Elon Musk Net Worth Over $400 Billion as Tesla Stock Hits New Highs

TSLA

Info

Spread

0.59

Spread (%)

0.6376 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Woensdag

14:31 - 20:59

Maandag

14:31-20:59

Dinsdag

14:31-20:59

Donderdag

14:31-20:59

Vrijdag

14:31-20:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

114719154176

Uitstaande aandelen

1246269952

Datum winstcijfer (volgende)

2013-01-28

Div. rend.

2024-12-30

Ex-dividenddatum

2024-12-13

Jaarlijks verwachte dividendpercentage

3.08

Jaarlijks verwachte dividendrendement

0.0335

Winst per aandeel

0.09

Meer informatie over dit instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten
Trustpilot
Live Chat